Latest Medivir News & Updates

See the latest news and media coverage for Medivir. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
Medivir

Drug discovery and development company

medivir.com
Headquarters
Huddinge, Sweden
Founded year
1988
Company type
Public company
Number of employees
2–50

Last updated

Latest news about Medivir

In short: Medivir AB progressed its clinical pipeline and improved its financial results, narrowing EBITDA losses for the first quarter of 2026.

Company announcements

  • Medivir

    Medivir holds annual general meeting

    Resolves on financial statements approval, board elections, remuneration, share issuance authorization, and incentive programme. Meeting occurred on 7 May 2026.

  • Medivir

    Medivir summons shareholders to AGM

    The meeting occurs on 7 May 2026 in Stockholm, with proposals for board elections, remuneration, share issue authorization, and a board incentive program.

  • Medivir

    Medivir publishes Q1 2026 interim report

    Net turnover SEK 1.0M, EBITDA -SEK 8.8M, cash SEK 149.1M. Key events include board changes, SEK 45M share issue, new CFO, and clinical progress on MIV-711 and VBX-1000.

  • Medivir

    Medivir publishes 2025 Annual Report

    The report highlights transformative 2025 achievements including fostrox study results, MIV-711 Orphan Drug Designation, funding via rights and share issues, and licensing deals. It announces planned Phase 2 studies.

Unlock all announcements with a

Media coverage

  • FinanzNachrichten

    Medivir AB: Resolutions at the Annual General Meeting in Medivir on 7 May 2026

    Medivir AB (publ) held its annual general meeting today on 7 May 2026. The annual general meeting was held by physical presence of shareholders and...

  • Dagens industri

    Medivir reduces the loss

    The specialist pharmaceutical company Medivir reports an EBITDA result for the first quarter of -8.8 million kronor (-12.6).

  • Yahoo Finance

    Earnings To Watch: Medivir AB (OSTO:MVIR) Reports Q1 2026 Result

    The consensus estimate for Q1 2026 revenue is $2.02 million, and the earnings are expected to come in at -$0.09 per share. The full year...

  • The Globe and Mail

    Medivir to Showcase Phase 2 Advances for Key Cancer and Bone Disease Programs

    Medivir AB ( (SE:MVIR)) just unveiled an announcement. Medivir AB, a Swedish pharmaceutical developer focused on high unmet medical needs, is advancing two key clinical...

Unlock all articles with a

Never miss news about Medivir

Track Medivir and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Medivir competitors & trending companies

Browse news for competitors to Medivir and other trending companies.